This third episode in KDIGO’s four-part IgAN series explores how to apply KDIGO guidance in real-world IgAN care through two illustrative patient cases. Building on earlier episodes in the series, the discussion highlights dynamic risk assessment, treatment selection, and monitoring strategies, along with practical decisions about RAS inhibitors versus DEARAs, TRF-budesonide versus systemic glucocorticoids, and the use of SGLT2 inhibitors. The episode also addresses complex scenarios, including rapidly progressive glomerulonephritis, nephrotic syndrome, acute kidney injury, pediatric IgAN, pregnancy, and treatment considerations in resource-limited settings. The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, United States), and features Gaia Coppock, MD (United States). Previous episodes in the series feature KDIGO IgAN Guideine Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, United States), and Shikha Wadwani, MD (Cedars-Sinai, United States). The fourth and final episode will be released in December 2025 and will focus on the challenges of implementing evidence-based guidance, emerging therapies, and key research needs.This podcast series was supported by Travere.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related